GINKGO BIOWORKS HOLDINGS INC (DNA)
US37611X1000 - Common Stock
Taking everything into account, DNA scores 4 out of 10 in our fundamental rating. DNA was compared to 84 industry peers in the Chemicals industry. No worries on liquidiy or solvency for DNA as it has an excellent financial health rating, but there are worries on the profitability. DNA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year DNA has reported negative net income.
In the past year DNA has reported a negative cash flow from operations.
In the past 5 years DNA always reported negative net income.
DNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -53.98%, DNA is not doing good in the industry: 95.24% of the companies in the same industry are doing better.
With a Return On Equity value of -86.48%, DNA is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.98% | ||
| ROE | -86.48% | ||
| ROIC | N/A |
ROA(3y)-74.96%
ROA(5y)-52.15%
ROE(3y)-108.06%
ROE(5y)-75.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 80.44%, DNA belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DNA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for DNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.42%
GM growth 5YN/A
2. Health
2.1 Basic Checks
DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNA has more shares outstanding than it did 1 year ago.
DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DNA has an Altman-Z score of -3.57. This is a bad value and indicates that DNA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of DNA (-3.57) is worse than 86.90% of its industry peers.
DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.57 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 5.34 indicates that DNA has no problem at all paying its short term obligations.
The Current ratio of DNA (5.34) is better than 92.86% of its industry peers.
DNA has a Quick Ratio of 5.34. This indicates that DNA is financially healthy and has no problem in meeting its short term obligations.
DNA has a Quick ratio of 5.34. This is amongst the best in the industry. DNA outperforms 94.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.34 | ||
| Quick Ratio | 5.34 |
3. Growth
3.1 Past
DNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.69%, which is quite impressive.
The Revenue for DNA has decreased by -46.49% in the past year. This is quite bad
The Revenue has been growing by 48.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q27.27%
Revenue 1Y (TTM)-46.49%
Revenue growth 3Y48.56%
Revenue growth 5YN/A
Revenue growth Q2Q-52.98%
3.2 Future
DNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.29% yearly.
The Revenue is expected to grow by 34.19% on average over the next years. This is a very strong growth
EPS Next Y31.23%
EPS Next 2Y19%
EPS Next 3Y16.41%
EPS Next 5Y12.29%
Revenue Next Year-13.6%
Revenue Next 2Y9.5%
Revenue Next 3Y17.91%
Revenue Next 5Y34.19%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as DNA's earnings are expected to grow with 16.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19%
EPS Next 3Y16.41%
5. Dividend
5.1 Amount
DNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GINKGO BIOWORKS HOLDINGS INC
NYSE:DNA (5/17/2024, 7:04:00 PM)
After market: 0.8149 +0.01 (+1.15%)0.8056
-0.03 (-3.98%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.68B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.98% | ||
| ROE | -86.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.34 | ||
| Quick Ratio | 5.34 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)57.69%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.23%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-46.49%
Revenue growth 3Y48.56%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y